-
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research.
-
SOR-C13 is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. SOR-C13 is used for Advanced Solid Tumors Research
-
EM127 is a potent and selectivity SMYD3 covalent inhibitor and impairs methyltransferase activity, can be used in SMYD3 positive tumours.
-
Apitolisib is a potent Class I PI3 kinase and mTORC1/2 inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, respectively.
-
Infigratinib is a potent inhibitor of the FGFR family, with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1/2/3/4, respectively.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
SG3199, a PBD dimer, is a warhead in next-generation ADCs with potently cytotoxic and a very short half-life.
-
Venadaparib is a selective and orally active PARP1/2 inhibitor with significant in vitro and in vivo activities in multiple cancer models.
-
Rosabulin is a small molecule vascular disrupting agent, with potential antimitotic and antineoplastic activities.
-
Barasertib (AZD1152) is a pro-drug of Barasertib-hQPA. A selective Aurora B kinase inhibitor. Provides a potential treatment for multiple myeloma.
Categories
Diseases
Others
Archives
- December 2022 (1)
- November 2022 (1)
- October 2022 (1)
- December 2021 (1)
- October 2021 (1)
- July 2021 (3)
- May 2021 (1)
- February 2021 (1)
- December 2020 (1)
- June 2020 (2)
- May 2020 (1)
- December 2019 (4)
- November 2019 (3)
- October 2019 (1)
- September 2019 (1)
- August 2019 (2)
- June 2019 (2)
- May 2019 (1)